Tumor necrosis factor in lung cancer: Complex roles in biology and resistance to treatment12
| Autor: | Gong, Ke, Guo, Gao, Beckley, Nicole, Zhang, Yue, Yang, Xiaoyao, Sharma, Mishu, Habib, Amyn A. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Lung Neoplasms
TNF Review Article TNFR2 TNF receptor 2 NSCLC OS overall survival EGFRwt EGFR wild type NSCLC non-small cell lung cancer Biomarkers Tumor Animals Humans EGFR inhibition Molecular Targeted Therapy PCA principal component analysis TNF tumor necrosis factor TMZ temozolomide NF-kappa B Disease Management Therapeutic resistance Genomics TCGA TKIs tyrosine kinase inhibitors TNFSFs TNF superfamily ligand Prognosis HR hazard ratio Gene Expression Regulation Neoplastic BATTLE Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination Treatment Outcome Drug Resistance Neoplasm Tumor Necrosis Factors GBM glioblastoma LPS lipopolysaccharides TCGA The Cancer Genome Atlas Immunotherapy Disease Susceptibility Biomarkers TNFR1 TNF receptor 1 |
| Zdroj: | Neoplasia (New York, N.Y.) |
| ISSN: | 1476-5586 1522-8002 |
| Popis: | Tumor necrosis factor (TNF) and its receptors are widely expressed in non-small cell lung cancer (NSCLC). TNF has an established role in inflammation and also plays a key role in inflammation-induced cancer. TNF can induce cell death in cancer cells and has been used as a treatment in certain types of cancer. However, TNF is likely to play an oncogenic role in multiple types of cancer, including NSCLC. TNF is a key activator of the transcription factor NF-κB. NF-κB, in turn, is a key effector of TNF in inflammation-induced cancer. Data from The Cancer Genome Atlas database suggest that TNF could be a biomarker in NSCLC and indicate a complex role for TNF and its receptors in NSCLC. Recent studies have reported that TNF is rapidly upregulated in NSCLC in response to targeted treatment with epidermal growth factor receptor (EGFR) inhibition, and this upregulation leads to NF-κB activation. The TNF upregulation and consequent NF-κB activation play a key role in mediating both primary and secondary resistance to EGFR inhibition in NSCLC, and a combined inhibition of EGFR and TNF can overcome therapeutic resistance in experimental models. TNF may mediate the toxic side effects of immunotherapy and may also modulate resistance to immune checkpoint inhibitors. Drugs inhibiting TNF are widely used for the treatment of various inflammatory and rheumatologic diseases and could be quite useful in combination with targeted therapy of NSCLC and other cancers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|